
In this exclusive video interview, Dr Amy Paller discusses two topics: 1) The importance of CCL17 (TARC) as a biomarker in pediatric patients with AD, and 2) How IL-4 and IL-13 contribute to skin barrier dysfunction in AD.

Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation

The ADVENT program will present a symposium to discuss diagnosis, pathophysiology, comorbidities of atopic dermatitis in children, as well as emerging treatment options for management of atopic dermatitis (AD) in children, who are candidates for systemic therapy at the 2024 European Academy of Paediatric Societies (EAPS) Congress.

This podcast episode looks at the epidemiology, clinical presentation and classification of atopic dermatitis of the hand and feet and the impact it has on patients' quality of life.